Raising FVE for Mesoblast after Adjusting for AUD as we Await 180 Day Survival Data in aGvHD
We are raising our fair value estimate for no-moat Mesoblast to AUD 2.90 from AUD 2.60 previously, after adjusting for the recent weakness in the Australian dollar/U.S. dollar exchange rate, which currently stands at 0.74. This is ahead of an expected readout of day 180 safety data from the ongoing phase 3 pediatric patients with steroid-refractory Acute Graft Versus Host Disease, or aGVHD, study of MSC-100-IV, in first-quarter fiscal 2019. However, our forecasts, which are denominated in U.S. d...Mesoblast is engaged in the development of regenerative medicine products. Co. has leveraged its proprietary technology platform, based on specialized cells known as mesenchymal lineage adult stem cells ("MLCs"), to establish a portfolio of late-stage product candidates. Co.'s allogeneic, "off the shelf" product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology and hematologic conditions. Each MLC-derived product candidate has technical characteristics, target indications, reimbursement strategy, commercialization potential, and partnering opportunities.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.